

APPENDIX A

Evidence Table

Author/Year	Study Design	Demographics	Diagnostic Accuracy	
Chiou, Sheu, Wang, Chang 2003	Case Reports Pre-op CT scans were obtained on patients with PSpC and were retrospectively reviewed. Serum CA-125 levels were recorded.	11 patients with PSpC	An elevated level of CA-125 was found in 91% of pts.	Sm No acc
Skates, Troiano, Knapp 2003	Case Study	Single patient	Report of only a rising level of CA-125	Sim
Wright, Horowitz, Rader 2002	Case Study	Single patient	Report of a CA-125 level of 2907 IU/ml	Sim
Zissin, Hertz, Altaras, Shapiro-Feinberg, Fishman 2001	Case Reports	36 patients age range 37-85	All patients had elevated levels of CA-125.	No acc
Furukawa, Ueda, Takahashi, Higashino, Shimura, Tsujimura, Araki 1999	Case Reports	3 patients, age range 44-71	CA-125 levels ranged from 3598 IU/ml to 11,110 IU/ml, and immunohistochemical staining for CA-125 was positive within tumor cells from all 3 patients.	Sm
Tsujimura, Takeda, Terada, Uramoto 1991	Case Reports	2 patients, aged 44 and 71	Study only notes CA-125 levels were considered elevated, and tumor cells showed positivity for CA-125.	Sm No acc
Altara, Aviram, Cohen, Cordoba, Weiss, Bayth 1991	Case Reports	38 patients involved in the study, 7 met criteria for PPC. Mean age 61.2	Study noted that CA-125 levels were available only for 3 cases.	CA for No acc
Kebapci, Yalcin, Dundar, Ozalp, Kaya 2003	Case Report	12 patients with mean age 57.5 (SD 10.3)	Study notes that all patients had elevated CA-125 levels	No acc
Kennedy, Markman, Webster, Kulp, Peterson, Rybicki, Belinson	Case Report	38 patients with PPC (36 stage IIIC and 2 stage IV)	92% of patients experienced at least a 50% reduction in CA-125 levels, and 55% of	Thi gen stag

1998			patients experienced > 90% reduction in CA-125 levels.	dis
Wick, Mills, Dehner, Bollinger, Fechner 2000	Comparative study evaluating immunohistochemistry between PPC and ovarian papillary carcinoma (OPC)	13 examples of PPC and 31 examples of OPC were used	Study noted PPC and OPC were similar in quantitative and qualitative reactivity for B72.3 antigen, CEA, Leu M1, CA-125, LN1, MB2, S100 protein, placenta alkaline phosphatase, and amylase. Residual non-neoplastic tissue failed to express any of these antigens except for cytokeratin, EMA, and CA-125	Stu me PP res qua rea
Piura, Meirovitz, Bartfeld, Yanai-Inbar, Cohen 1998	Case Report to compare similarities between patients with PPC and OPC	15 patients with PPC and 52 patients with stage III-IV OPC were compared.	Study notes that with regard to patient's characteristics, presenting signs and symptoms, type and extent of surgery, tumor response to first-line and second-line chemotherapy, recurrence-free interval, recurrence site, and CA-125, no significant differences were noted between both types of tumors	No acc NP of a 125 tum (wh lev sig
Barda, Menczer, Chetrit, Beck, Piura, Glezerman, Modan, Sadetzki, National Israel Ovarian Cancer Group 2004	Case Report to compare similarities between patients with PPC and OPC	95 patients with PPC were compared to 117 FIGO stage III-IV OPC.	Study only notes similarities between the 2 groups-but did note higher rates of abdominal distension, volume of ascites, and malignant cells in ascitic fluid, and lower rate of pelvic palpable mass and personal history of breast cancer were noted in PPC than in OPC. Study did not include CA-125 as a variable	CA stu
Rose, Reale 1991	Case Report	2 cases of advanced PPC, both patients had previously had a hysterectomy and salpingo-oophorectomy for endometrial carcinoma	Study notes that both subjects had elevated CA-125 levels which were being routinely followed because of history of previous endometrial carcinoma	Sm No abc test
Eltabbakh, Piver, Natarajan, Mettlin 1998	Epidemiological study examining differences between women with PPC and OPC	Compares 50 women with PPC with 503 women with OPC between Oct 82 and Oct 96 followed at Roswell Park Center Institute using a self-administered questionnaire	Few significant differences were found between the 2 groups, though patients with PPC significantly older, had later menarche, and used less perineal talc powder	Thi to t dia, rev 2 g
Piura, Rabinovich, Yanai-Inbar 2001	Study designed to determine association between BRCA mutation and primary malignancies	3 primary malignancies related to BRCA 185delAG mutation were used to determine association with primary malignancies	Immunochemical staining revealed that breast cancer, PPC, and OPC were associated with this mutation	Thi to c mu ma tell wer spe

				use dia, Stu if p pre PPC det dia,
Piver, Jishi, Tsukada, Nava 1993	Study designed to determine if women who elected to have a prophylactic oophorectomy due to a family history of ovarian cancer would go on to later develop PPC	324 women with a family history of ovarian cancer had a prophylactic oophorectomy and were followed for 1-27 years	6 of these patients developed PPC	
Levine, Argenta, Yee, Marshall, Narciso, Bogomolny, Rahaman, Robson, Offit, Barakat, Soslow, Boyd 2003	Study designed to determine the incidence of BRCA mutation among Ashkenazi Jewish patients with fallopian tube carcinoma (FTC) or PPC	29 patients with FTC and 22 patients with PPC were genotyped for the 3 Ashkenazi Jewish BRCA found mutations (185DEL ag, 5382insC, and 6174delT)	BRCA mutation was found in 17% of FTC patients, and found in 41% of patients with PPC. Mutation carriers had a younger age at diagnosis than patients without mutation. For BRCA mutation carriers, the lifetime risk of FTC and PPC were 0.6% and 1.3% respectively	Thi to t of C asse inc Ash and
Killackey Davis 1993	Study designed to compare OPC to PPC	Of 199 patients that underwent laparotomy for OPC, 15% of cases had PPC	Mean cytoreduction in the PPC group was 65% compared to 79% for the OPC group; Also patients with PPC had shorter disease-free interval, shorter overall survival time	Thi to t of C asse OP
Mills, Anderson, Fechner, Austin 1998	A clinicopathological study to compare PPC with Stage III-IV OPC	10 patients with PPC were compared to 16 patients with OPC	PPC had significantly worst prognosis than patients with OPC (as measured by median disease free interval, median survival, and predicted 5-year survival	Thi to t of C asse OP